The primary objective is to determine the safety of a single IV dose of ABX-IL8 in the treatment of patients with plaque psoriasis involving greater than 3% of the body surface area. This is a multicenter, randomized, placebo-controlled, dose rising clinical trial examining the safety of administering a single intravenous infusion of ABX-IL8 in patients with moderate to severe plaque psorasis. The next dose level will be based on accumulated safety information as defined in the protocol.
Showing the most recent 10 out of 1380 publications